Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease

Yurdaydin, Cihan; Keskin, Onur; Kalkan, Cagdas; Karakaya, Fatih; Caliskan, Aysun; Kabacam, Gokhan; ÖNDER, FATİH; Karatayli, Senem; Karatayli, Ersin; Deda, Xheni; Bozkaya, Hakan; Bozdayi, A.; İDİLMAN, RAMAZAN

doi:10.1093/infdis/jix656

Interferon Treatment Duration in Patients With Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease

Yurdaydin C., Keskin O., Kalkan C., Karakaya F., Caliskan A., Kabacam G., ...Daha Fazla

JOURNAL OF INFECTIOUS DISEASES, cilt.217, sa.8, ss.1184-1192, 2018 (SCI-Expanded, Scopus)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 217 Sayı: 8
Basım Tarihi: 2018
Doi Numarası: 10.1093/infdis/jix656
Dergi Adı: JOURNAL OF INFECTIOUS DISEASES
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1184-1192
Anahtar Kelimeler: Hepatitis B, interferon treatment, hepatocellular carcinoma, liver-related mortality, HBsAg clearance, HIV-INFECTED PATIENTS, HDV RNA RELAPSE, PEGYLATED INTERFERON-ALPHA-2B, COINFECTED PATIENTS, ALPHA THERAPY, VIRUS, TENOFOVIR, EFFICACY, REPLICATION, COMBINATION
Açık Arşiv Koleksiyonu: AVESİS Açık Erişim Koleksiyonu
Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Hayır

Özet

Background. Interferon is the only treatment option in chronic delta hepatitis (CDH). A CDH database (333 patients, 161 with interferon treatment history) was analyzed for effects of treatment duration on virologic response and clinical outcomes.